{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["Plasencia-Rodriguez C"],"pubmed_abstract":["<h4>Background</h4>The EXXELERATE study revealed poorer clinical outcomes in patients treated with adalimumab (ADL) and baseline rheumatoid factor (RF) above 203 IU/mL. However, responses were similar in patients treated with certolizumab pegol (CZP) regardless of RF levels.<h4>Objectives</h4>This study investigated the impact of RF levels >203 IU/mL on TNF inhibitors (TNFi) serum levels and the association with secondary nonresponse in RA patients treated with TNFi.<h4>Methods</h4>We performed an observational ambispective study with RA patients treated with infliximab (IFX), ADL, or CZP. Patients were stratified according to baseline RF levels: ≤ or >203 IU/mL. After 6 months, serum drug levels and antidrug antibodies were measured, and reasons for discontinuation were collected.<h4>Resu"],"journal":["Frontiers in medicine"],"pagination":["1461396"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11410080"],"repository":["biostudies-literature"],"pubmed_title":["Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients."],"pmcid":["PMC11410080"],"pubmed_authors":["Villalba-Yllan A","Nozal P","Plasencia-Rodriguez C","Balsa A","Bonilla G","Gehin JE","Pascual-Salcedo D","Martinez-Feito A","Almiron MD","Novella-Navarro M","Nuno L","Perez De Diego R"],"additional_accession":[]},"is_claimable":false,"name":"Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.","description":"<h4>Background</h4>The EXXELERATE study revealed poorer clinical outcomes in patients treated with adalimumab (ADL) and baseline rheumatoid factor (RF) above 203 IU/mL. However, responses were similar in patients treated with certolizumab pegol (CZP) regardless of RF levels.<h4>Objectives</h4>This study investigated the impact of RF levels >203 IU/mL on TNF inhibitors (TNFi) serum levels and the association with secondary nonresponse in RA patients treated with TNFi.<h4>Methods</h4>We performed an observational ambispective study with RA patients treated with infliximab (IFX), ADL, or CZP. Patients were stratified according to baseline RF levels: ≤ or >203 IU/mL. After 6 months, serum drug levels and antidrug antibodies were measured, and reasons for discontinuation were collected.<h4>Resu","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-18T19:42:27.676Z","creation":"2025-04-07T07:31:27.048Z"},"accession":"S-EPMC11410080","cross_references":{"pubmed":["39296891"],"doi":["10.3389/fmed.2024.1461396"]}}